Policies,Clinical,UWMF Clinical,UWMF-wide,Clinical Policies and Procedures,Medications, Drug-Specific

Reclast-Zoledronic Acid (102.083)

Reclast-Zoledronic Acid (102.083) - Policies, Clinical, UWMF Clinical, UWMF-wide, Clinical Policies and Procedures, Medications, Drug-Specific



TITLE: Reclast/ Zoledronic Acid

Effective Date: January 9, 2008 Approval: See Authorization
Supersedes Protocol: None Contact: Clinical Staff Education

Reviewed January, 2008 May, 2009 August 2011

PURPOSE: To provide guidelines for administration: Reclast/ Zoledronic Acid at UWMF
DEFINITION: Reclast is a bisphosphanate that decreases bone turnover. Reclast is not
to be given to patients with a history of asthma/aspirin sensitivity
Reclast is used to treat or prevent osteoporosis.

POLICY: The clinical staff will utilize the following guidelines to properly administer:
Reclast to UWMF patients.

SUPPLIES: Provider’s order, patient’s record, labeled medication bottle with
appropriate drug dose, medication pump (if available), vented tubing, non-sterile gloves,
IV start kit, pressure dressing.


1. Check the name and dose of medication against the provider’s order. Clarify any

2. Complete patient assessment and lab findings relevant to medication.
Within one month prior to administration of Reclast infusion obtain Creatinine,
Calcium, Vitamin D by HPLC assay level (Done at UW).
NOTE: If the following labs are not within normal ranges contact provider prior
to administration.
 Creatinine (0.4-1.2mg/dl).
 Calcium is not 8.4 to 10.4 mg/dL
 Vitamin D by HPLC (30-80 ng)
Obtain patient’s vital signs.
Review patient’s drug allergies

3. Review medication order, adhering to the five rights of drug administration.
Right – drug, dose, time, route, patient
Check the expiration date of the medication

4. Identify the patient and provide privacy for the procedure.

5. Wash hands and apply gloves.

6. Start IV, obtaining a positive blood return.
Prime with 250ml Normal Saline

7. Tape the IV in place.

8. Administer 5 mg/100mL Reclast over no less than 30 minutes.

9. Remove IV and apply a pressure dressing.

10. Allow the patient to remain in the waiting room for 30 minutes to observe for any
adverse reactions.

11. In the patient’s record document the following:
Lab results
Vital signs
Date, drug name, lot#, manufacturer, NDC#, dose, time, and expiration date
IV procedure – IV site, catheter size and fluid used and infused
Educational instructions given to patient
How the patient tolerated the procedure
Follow-up care or appointment (if needed)

WRITTEN BY: Danielle Varnell, R.N., Clinical Staff Educator

REVISED BY: LaVay Morrison RN, Clinical Staff Educator

REVIEWED BY: JoEllen Lease, RN Case Manager Rheumatology

REFERENCES: Novartis, UWHC Laboratory


Medical Director Date